We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
+10.34%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$5.32B
AUM Growth
+$623M
(+13%)
Cap. Flow
+$473M
Cap. Flow
% of AUM
8.88%
Top 10 Holdings %
Top 10 Hldgs %
31.02%
Holding
1,563
New
308
Increased
332
Reduced
859
Closed
60
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Equinix
EQIX
|
+$43.7M |
| 2 |
American Tower
AMT
|
+$34.7M |
| 3 |
Crown Castle
CCI
|
+$21.3M |
| 4 |
CD
Chindata Group Holdings Limited American Depositary Shares
CD
|
+$19.1M |
| 5 |
CONE
CyrusOne Inc Common Stock
CONE
|
+$13.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$80.9M |
| 2 |
Microsoft
MSFT
|
+$63.9M |
| 3 |
Amazon
AMZN
|
+$61.8M |
| 4 |
Meta Platforms (Facebook)
META
|
+$26.4M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$24.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 18.33% |
| 2 | Technology | 16.44% |
| 3 | Consumer Discretionary | 8.8% |
| 4 | Healthcare | 7.69% |
| 5 | Communication Services | 7.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1176
Intellia Therapeutics
NTLA
$1.48B
| $134K | ﹤0.01% |
2,471
-208
| -8% | -$7.55K |
|
1177
Alnylam Pharmaceuticals
ALNY
$38.5B
| $133K | ﹤0.01% |
1,022
+184
| +22% | +$24.6K |
|
1178
Seres Therapeutics
MCRB
$45.8M
| $133K | ﹤0.01% |
+272
| New | +$159K |
|
|
SGMO
1179
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $133K | ﹤0.01% |
8,494
+594
| +8% | +$6.96K |
|
1180
Daktronics
DAKT
$929M
| $132K | ﹤0.01% |
28,311
+18,784
| +197% | +$82.2K |
|
1181
Twist Bioscience
TWST
$5.32B
| $131K | ﹤0.01% |
928
-1,012
| -52% | -$112K |
|
|
CLVS
1182
DELISTED
Clovis Oncology, Inc.
CLVS
| $131K | ﹤0.01% |
27,289
+11,738
| +75% | +$59.4K |
|
|
BPMC
1183
DELISTED
Blueprint Medicines
BPMC
| $129K | ﹤0.01% |
1,152
-350
| -23% | -$36.9K |
|
1184
Karyopharm Therapeutics
KPTI
$155M
| $129K | ﹤0.01% |
557
+138
| +33% | +$32K |
|
|
BHVN
1185
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $129K | ﹤0.01% |
+1,505
| New | +$128K |
|
|
CIVI
1186
DELISTED
Civitas Resources
CIVI
| $128K | ﹤0.01% |
+6,636
| New | +$139K |
|
1187
Insteel Industries
IIIN
$609M
| $128K | ﹤0.01% |
5,767
-1,968
| -25% | -$44.6K |
|
1188
Fate Therapeutics
FATE
$265M
| $127K | ﹤0.01% |
1,398
-2,020
| -59% | -$125K |
|
|
WW
1189
DELISTED
WW International
WW
| $127K | ﹤0.01% |
5,209
-6,060
| -54% | -$158K |
|
|
DCPH
1190
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $127K | ﹤0.01% |
2,226
+288
| +15% | +$17.1K |
|
1191
Alkermes
ALKS
$8.23B
| $125K | ﹤0.01% |
+6,244
| New | +$114K |
|
|
ALLK
1192
DELISTED
Allakos
ALLK
| $125K | ﹤0.01% |
893
-506
| -36% | -$52.7K |
|
1193
Beam Therapeutics
BEAM
$2.65B
| $125K | ﹤0.01% |
+1,533
| New | +$75.4K |
|
1194
Ultragenyx Pharmaceutical
RARE
$2.5B
| $125K | ﹤0.01% |
905
-638
| -41% | -$75.7K |
|
|
TBRG
1195
DELISTED
TruBridge
TBRG
| $125K | ﹤0.01% |
4,639
+1,574
| +51% | +$44.4K |
|
1196
PTC Therapeutics
PTCT
$6.21B
| $124K | ﹤0.01% |
2,031
-102
| -5% | -$6.01K |
|
1197
Iovance Biotherapeutics
IOVA
$2.03B
| $123K | ﹤0.01% |
2,645
-916
| -26% | -$36.4K |
|
1198
Allogene Therapeutics
ALLO
$573M
| $122K | ﹤0.01% |
4,830
+2,318
| +92% | +$75.6K |
|
|
MRTX
1199
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $122K | ﹤0.01% |
554
-472
| -46% | -$102K |
|
|
KYNB
1200
Kyntra Bio
KYNB
$28.2M
| $120K | ﹤0.01% |
129
+19
| +17% | +$20K |
|
Similar funds
SAM
Pacer Advisors's Q4 2020 Portfolio in Review
As of Q4 2020, Pacer Advisors held 1,563 positions worth $5.32B, up 13% from $4.7B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Pacer Advisors deployed $473M of net new capital in Q4 2020, opening 308 new positions and adding to 332 existing holdings. Its largest new stake was Chindata Group Holdings Limited American Depositary Shares: 1,166,530 shares worth $27.9M.
By sector, the portfolio is most concentrated in Real Estate at 18% of assets, up from 17% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $80.9M trimmed.
- Pacer Advisors's largest Q4 2020 buy was Chindata Group Holdings Limited American Depositary Shares: 1,166,530 shares worth $27.9M.
- Pacer Advisors added most to Equinix in Q4 2020, an estimated $43.7M increase.
- Pacer Advisors's biggest Q4 2020 reduction was Apple, cutting an estimated $80.9M.
- Pacer Advisors fully exited INDUS Realty Trust, Inc. (MD) Common Stock in Q4 2020, selling an estimated $1.83M.
- Pacer Advisors's ten largest holdings make up 31% of its $5.32B portfolio in Q4 2020.
- Pacer Advisors opened 308 new positions and closed 60 in Q4 2020.
- Pacer Advisors's portfolio value rose 13% quarter-over-quarter to $5.32B.
Based on Pacer Advisors's 13F filing for Q4 2020, filed 20 Jan 2021.